Interestingly, SABR in less than 10 Gy per fx for early-stage NSCLC has been reported to increase the fraction of proliferating CD4+ and CD8+ circulating T-cells, which may contribute to a systemic immune response [26]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.